Marksans Pharma's Q3 FY 2025-26 Quarterly Results
- 06 Feb 2026
Result Summary
- Marksans Pharma Ltd reported a 4.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.1%.
- Its expenses for the quarter were up by 2.5% QoQ and 10.2% YoY.
- The net profit increased 14.7% QoQ and increased 8.2% YoY.
- The earnings per share (EPS) of Marksans Pharma Ltd stood at 2.5 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 774.57 | 741.98 | 709.70 | 4.4% | 9.1% |
Total Expenses | 623.95 | 608.66 | 566.44 | 2.5% | 10.2% |
Profit Before Tax | 150.62 | 133.33 | 143.26 | 13.0% | 5.1% |
Tax | 36.93 | 34.20 | 38.19 | 8.0% | -3.3% |
Profit After Tax | 113.69 | 99.14 | 105.06 | 14.7% | 8.2% |
Earnings Per Share | 2.50 | 2.17 | 2.31 | 15.2% | 8.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Marksans Pharma Ltd is a pharmaceutical company involved in the development, manufacturing, and marketing of pharmaceutical formulations. The company operates primarily in the healthcare industry, producing a range of products that include over-the-counter (OTC) medications and prescription drugs. Marksans Pharma is known for its diverse portfolio, which encompasses various therapeutic segments such as cardiovascular, anti-diabetic, and central nervous system drugs, among others. For the latest quarter, no specific recent major developments are provided, but the company continues to focus on expanding its market presence and enhancing its product offerings.
Revenue
During the third quarter of fiscal year 2026 (Q3FY26), Marksans Pharma Ltd reported a total income of ₹774.57 crores. This marks an increase of 4.4% compared to the previous quarter (Q2FY26), where the total income was ₹741.98 crores. On a year-over-year basis, the total income grew by 9.1% from ₹709.70 crores in Q3FY25. This positive growth in revenue indicates a steady upward trend in the company’s financial performance over the observed periods.
Profitability
For Q3FY26, the company’s profit before tax was ₹150.62 crores, reflecting a quarter-over-quarter increase of 13.0% from ₹133.33 crores in Q2FY26 and a year-over-year rise of 5.1% from ₹143.26 crores in Q3FY25. The tax expense for the quarter was ₹36.93 crores, up by 8.0% from the previous quarter but down by 3.3% compared to the same quarter last year. Profit after tax stood at ₹113.69 crores, showing a significant increase of 14.7% QoQ and 8.2% YoY from ₹99.14 crores and ₹105.06 crores, respectively. The earnings per share also increased by 15.2% QoQ and 8.2% YoY, amounting to ₹2.50 for Q3FY26.
Operating Metrics
Marksans Pharma Ltd’s total expenses for Q3FY26 were recorded at ₹623.95 crores, which is a 2.5% increase from the ₹608.66 crores reported in Q2FY26 and a 10.2% rise from ₹566.44 crores in Q3FY25. The proportionate rise in total expenses alongside revenue growth suggests consistent operational activity. The financial data provided does not include specific information on key financial ratios such as P/E ratio, debt-to-equity ratio, or current ratio, hence these cannot be calculated or analyzed in this report. Nonetheless, the growth in both revenue and profitability metrics highlights the company's operational resilience within its market segment.